Loading Audio Player...

Episode Description:

On today’s show, we’ll discuss a continuing empty room – an opportunity ignored by most investors because they either don’t want to or can’t participate. We’ve shared conversations under the theme about investing in Venezuela, Africa, CLO equity, tax assets, and biotech. Among them, biotech is a room that just keeps getting emptier, so I thought it would be fun to pay it another visit.

Rod Wong is the founder and Managing Partner of RTW Investments, a life sciences-focused investment and innovation firm of 80 professionals that manages $6 billion in assets.

I had a chance to drop by Rod’s office in NYC and discuss his background, case for life sciences, investment and business approach, investment process across sourcing ideas, research, probability assessment of binary outcomes, portfolio construction, competition, and outlook.

Show Notes
03:20 Background in medicine
05:16 Path to biotech investing
08:13 Case for life sciences
10:47 Innovation in biotech
12:24 Founding RTW
15:33 Building and managing a multi-functional team
22:23 Filtering investment opportunities
27:27 Assessing science, business and management
34:51 Portfoio construction
39:50 Market structure in biotech
44:53 Competitive environment
47:59 Opportunities
50:24 Risks
51:37 Positioning RTW for the future
52:57 Closing questions

Most Recent Episodes:

The content and use of these transcripts is intended for the use of premium members only. Unless expressly granted permission by Ted, each corporate subscriber can share transcripts within their organization (if less < 50 employees) and both corporate and individuals subscribers can share two (2) transcripts with two (2) non-paying members, after which any non-paying members should consider a membership.

All opinions expressed by Ted and podcast guests are solely their own opinions and do not reflect the opinion of the firms they represent. This podcast is for informational purposes only and should not be relied upon as a basis for investment decisions.